Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526741 · ClinicalTrials.gov registry record
ASF Alport Patient Registry
A clinical trial of Alport Syndrome and Thin Basement Membrane Disease, sponsored by Alport Syndrome Foundation.
- Recruiting
- Registry status
- 2,500
- Enrollment target
- 1
- Study location
NCT06526741: Recruiting study of Alport Syndrome and Thin Basement Membrane Disease, sponsored by Alport Syndrome Foundation.
NCT06526741 is a study of Alport Syndrome and Thin Basement Membrane Disease that is actively recruiting participants, run by Alport Syndrome Foundation. The registered enrollment target is 2,500 participants, above the 119-participant average among 5 other Alport Syndrome trials with a reported enrollment target (2001% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06526741, a study of Alport Syndrome and Thin Basement Membrane Disease, is actively recruiting participants, sponsored by Alport Syndrome Foundation.
- RECRUITING
- Registry status
- 2,500 participants
- Enrollment target
- 1
- Study location
Study Summary
Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US territories and outlying islands. The Registry welcomes participants of all ages who have a confirmed clinical diagnosis of Alport syndrome. A confirmed diagnosis could be obtained via genetic testing, biopsy, and/or from a medical professional's clinical assessment of the individual's symptoms and/or family history. Participants can have any form and stage of this disease to be eligible for inclusion in the Registry. Patient participation in the Registry is crucial to helping attract and advance research, understanding understudied aspects of the disease, and informing clinical trials that may lead to Alport syndrome therapies and/or a cure. The Registry is accessed through a secure, online application. Participants report their own health history in the Registry and are encouraged to update any changes, at most, every three months. The security of each participant's information is a top priority. Any detail that could identify an individual participant is kept confidential in the Registry and such data are de-identified to protect the participant's privacy. No electronic health records or social security numbers are requested by or connected to the Registry. A parent or legal guardian may consent to enroll a child/dren Alport patient(s) under the age of 18 years. An additional assent form is used for individuals ages 7-17. At age 18, participants will be required to re-consent as an adult if they choose to continue to participate in the Registry.
Primary Outcome
Reach 750 enrolled participants
Conditions Studied
Interventions
- OTHER Longitudinal data collection
Study Locations (1)
Arizona
- On-line only: https://asfalportpatientregistry.healthie.net - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2023-08-24 |
| Est. Completion | 2048-08-23 |
What NCT06526741 shows while recruiting
NCT06526741 is an observational study that tracks outcomes without assigning an intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 119-participant average among 5 other Alport Syndrome trials with a reported enrollment target (2001% higher).
The record links to 3 conditions, with Alport Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Longitudinal data collection is the first listed.
NCT06526741 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06526741 about?
NCT06526741 is a clinical study titled "ASF Alport Patient Registry". Alport Syndrome Foundation's (ASF's) Alport Patient Registry (the Registry) is open to individuals living with Alport syndrome in the United States (US) and US territories and outlying islands. The Registry welcomes participants of all ages who have a confirmed clinical diagnosis of Alport syndrome....
What is the current status of trial NCT06526741?
This trial is currently recruiting. The enrollment target is 2,500 participants. The study started on 2023-08-24. Estimated completion is 2048-08-23.
What conditions does trial NCT06526741 study?
This clinical trial studies the following conditions: Alport Syndrome, Thin Basement Membrane Disease, Hereditary Nephritis.
What interventions are being tested in trial NCT06526741?
The interventions under investigation include: Longitudinal data collection (OTHER).
Who is sponsoring clinical trial NCT06526741?
This trial is sponsored by Alport Syndrome Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526741 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alport Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RECRUITING · Phase 2
-
NEPTUNE Match Study
RECRUITING · NA
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
COMPLETED
-
A Study of RG-012 in Subjects With Alport Syndrome
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI